Pharmacology active microcarriers delivering HGF associated with extracellular vesicles for myocardial repair

Author(s):  
Melody Riaud ◽  
Grégory Hilairet ◽  
Laurence Sindji ◽  
Liliana Perdomo ◽  
Claudia N. Montero-Menei ◽  
...  
2021 ◽  
Vol 116 (1) ◽  
Author(s):  
Ji-Hye Jung ◽  
Gentaro Ikeda ◽  
Yuko Tada ◽  
Daniel von Bornstädt ◽  
Michelle R. Santoso ◽  
...  

Pharmaceutics ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 1195
Author(s):  
Melody Riaud ◽  
M. Carmen Martinez ◽  
Claudia N. Montero-Menei

Clinical studies have demonstrated the regenerative potential of stem cells for cardiac repair over the past decades, but their widespread use is limited by the poor tissue integration and survival obtained. Natural or synthetic hydrogels or microcarriers, used as cell carriers, contribute to resolving, in part, the problems encountered by providing mechanical support for the cells allowing cell retention, survival and tissue integration. Moreover, hydrogels alone also possess mechanical protective properties for the ischemic heart. The combined effect of growth factors with cells and an appropriate scaffold allow a therapeutic effect on myocardial repair. Despite this, the effects obtained with cell therapy remain limited and seem to be equivalent to the effects obtained with extracellular vesicles, key actors in intercellular communication. Extracellular vesicles have cardioprotective effects which, when combined proangiogenic properties with antiapoptotic and anti-inflammatory actions, make it possible to act on all the damages caused by ischemia. The evolution of biomaterial engineering allows us to envisage their association with new major players in cardiac therapy, extracellular vesicles, in order to limit undesirable effects and to envisage a transfer to the clinic. This new therapeutic approach could be associated with the release of growth factors to potentialized the beneficial effect obtained.


2021 ◽  
Vol 8 ◽  
Author(s):  
Chunping Liu ◽  
Nathan Bayado ◽  
Dongyue He ◽  
Jie Li ◽  
Huiqi Chen ◽  
...  

Cardiovascular disease is the leading cause of human death worldwide. Drug thrombolysis, percutaneous coronary intervention, coronary artery bypass grafting and other methods are used to restore blood perfusion for coronary artery stenosis and blockage. The treatments listed prolong lifespan, however, rate of mortality ultimately remains the same. This is due to the irreversible damage sustained by myocardium, in which millions of heart cells are lost during myocardial infarction. The lack of pragmatic methods of myocardial restoration remains the greatest challenge for effective treatment. Exosomes are small extracellular vesicles (EVs) actively secreted by all cell types that act as effective transmitters of biological signals which contribute to both reparative and pathological processes within the heart. Exosomes have become the focus of many researchers as a novel drug delivery system due to the advantages of low toxicity, little immunogenicity and good permeability. In this review, we discuss the progress and challenges of EVs in myocardial repair, and review the recent development of extracellular vesicle-loading systems based on their unique nanostructures and physiological functions, as well as the application of engineering modifications in the diagnosis and treatment of myocardial repair.


Sign in / Sign up

Export Citation Format

Share Document